A press release was issued by Strongbridge on September 8th, 2020, entitled “Strongbridge Biopharma’s Recorlev successful in Cushing’s syndrome study.” While this press release reported “positive results from [Strongbridge’s] 44-subject Phase 3 clinical trial, LOGIC, evaluating Recorlev (levoketoconazole) in patients with endogenous Cushing’s syndrome,” treatment-emergent adverse events” that included “nausea (29%), hypokalemia (28%), headache (21%), hypertension (19%) and diarrhea (15%).” were also disclosed in this press release.
Strongbridge’s stock price fell $0.71 per share, or 20.11%, on this news, to close at $2.82 per share on September 8, 2020.
Strongbridge Biopharma, plc
Investors that purchased the Company’s securities and have suffered a loss, please fill in transaction information below, or email to firstname.lastname@example.org.
There is no cost or obligation associated with submitting your information. If you are a shareholder who suffered a loss, please submit your contact information and purchase information to participate in the putative class action.
We also encourage you to contact Lesley F. Portnoy of The Portnoy Law Firm, at 310.692.8883, to discuss your rights free of charge. You can also reach us through the firm’s website at www.portnoylaw.com, or by email at email@example.com.
If you choose to take no action, you can remain an absent class member.
Joining the case through the Portnoy Law website enables investors to learn about their legal claims and take an active role in recovering their losses.
The Portnoy Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.
Portnoy Law Firm
Lesley F. Portnoy, Esq.,
8240 Beverly Blvd., Suite 9
Los Angeles, CA 90048